BackgroundCheck.run
Search For

Subhash C Sinha, 65500 E 63Rd St APT 12F, New York, NY 10065

Known as:
Subhash A Sinha Santosh C Sinha Subhas Sinha

Subhash Sinha Phones & Addresses

500 E 63Rd St APT 12F, New York, NY 10065   

13459 Tiverton Rd, San Diego, CA 92130    858-3509225   

La Jolla, CA   

Pittsburgh, PA   

Escondido, CA   

4663 Dunham Way, San Diego, CA 92130    858-3509225   

Work

Position: Clerical/White Collar

Education

Degree: High school graduate or higher
Get Report
Control this profile

Mentions for Subhash C Sinha

Subhash Sinha resumes & CV records

Resumes

Subhash Sinha Photo 25

Research Associate Professor

Location:
San Diego, CA
Industry:
Research
Work:
Rockefeller University
Research Associate Professor The Scripps Research Institute 1999 - 2013
Associate Professor The Scripps Research Institute 1994 - 1999
Assistant Professor The Scripps Research Institute 1991 - 1994
Postdoctoral Research Associate Technion - Israel Institute of Technology 1989 - 1991
Postdoctoral Fellow Tohoku University 1987 - 1989
Monbusho Postdoctoral Fellow
Education:
Banaras Hindu University 1983 - 1987
Doctorates, Doctor of Philosophy, Philosophy, Chemistry Patna University 1978 - 1983
Master of Science, Masters, Organic Chemistry
Skills:
Drug Discovery, Organic Synthesis, Medicinal Chemistry, Biochemistry, Organic Chemistry, Drug Design, Natural Products, R&D, Antibodies, Protein Chemistry, Life Sciences, Purification, Assay Development, Synthetic Organic Chemistry, Lifesciences, Oncology, Neuroscience
Subhash Sinha Photo 26

Subhash Sinha

Subhash Sinha Photo 27

Associate Professor At Tsri

Position:
Associate Professor at TSRI
Location:
Greater San Diego Area
Industry:
Higher Education
Work:
TSRI
Associate Professor

Publications & IP owners

Us Patents

Antibody Targeting Compounds

US Patent:
8252902, Aug 28, 2012
Filed:
Oct 22, 2002
Appl. No.:
10/278364
Inventors:
Carlos F. Barbas - Solana Beach CA, US
Christoph Rader - San Diego CA, US
Subhash C. Sinha - San Diego CA, US
Richard A. Lerner - La Jolla CA, US
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
C07K 16/00
US Classification:
5303871, 424 934, 4241301, 4241781, 4241791
Abstract:
The present invention provides antibody targeting compounds in which the specificity of the antibody has been reprogrammed by covalently or noncovalently linking a targeting agent to the combining site of an antibody. By this approach, the covalently modified antibody takes on the binding specificity of the targeting agent. The compound may have biological activity provided by the targeting agent or by a separate biological agent. Various uses of the invention compounds are provided.

Integrin Targeting Compounds

US Patent:
2003012, Jul 10, 2003
Filed:
Oct 22, 2002
Appl. No.:
10/278539
Inventors:
Carlos Barbas - Solana Beach CA, US
Christoph Rader - San Diego CA, US
Subhash Sinha - San Diego CA, US
Assignee:
The Scripps Research Institute
International Classification:
A61K039/395
A61K031/5513
A61K031/55
C 07D 4 3/14
C07K016/28
US Classification:
424/144100, 514/212070, 514/221000, 530/388220, 540/500000, 540/523000
Abstract:
The present invention is directed to integrin targeting compounds comprising an integrin targeting component linked to a functional component such as a therapeutic agent or antibody. Structures of various integrin targeting compounds are provided. Additionally provided are methods of delivering a functional component to integrin associated with cells or tissue of an individual using the integrin targeting compounds. Also provided are methods of treating or preventing a disease or condition in an individual using the wherein said disease or condition involves an integrin using the integrin targeting compounds.

Antibody Targeting Compounds

US Patent:
2003019, Oct 9, 2003
Filed:
Apr 21, 2003
Appl. No.:
10/420373
Inventors:
Carlos Barbas - Solana Beach CA, US
Christoph Rader - San Diego CA, US
Subhash Sinha - San Diego CA, US
Richard Lerner - La Jolla CA, US
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
G01N033/53
A61K039/395
A61K038/05
C12N009/00
US Classification:
435/007100, 435/188500, 514/018000, 424/130100
Abstract:
The present invention provides antibody targeting compounds in which the specificity of the antibody has been reprogrammed by covalently or noncovalently linking a targeting agent to the combining site of an antibody. By this approach, the covalently modified antibody takes on the binding specificity of the targeting agent. The compound may have biological activity provided by the targeting agent or by a separate biological agent. Various uses of the invention compounds are provided.

Use Of Retro-Aldol Reaction To Generate Reactive Vinyl Ketone For Attachment To Antibody Molecules By Michael Addition Reaction For Use In Immunostaining And Immunotargeting

US Patent:
2008021, Sep 4, 2008
Filed:
Jul 6, 2007
Appl. No.:
11/774149
Inventors:
Subhash C. Sinha - San Diego CA, US
Carlos F. Barbas - Solana Beach CA, US
Richard A. Lerner - San Diego CA, US
Assignee:
THE SCRIPPS RESEARCH INSITUTE - La Jolla CA
International Classification:
A61K 39/395
A61P 35/00
C07K 16/00
C07K 1/00
C07K 5/10
US Classification:
4241301, 5303871, 530330, 530300
Abstract:
The present invention is directed to methods for formation of a chemically programmed antibody comprising the steps of: (1) reacting a conjugate comprising a signal module covalently linked to a proadapter with a catalytic moiety selected from the group consisting of a catalytic antibody and a Fab fragment of a catalytic antibody, wherein the proadapter includes therein a precursor to a reactive moiety activated to a reactive moiety by a reaction catalyzed by the catalytic moiety; and (2) crosslinking the reactive moiety to a side chain of an amino acid residue in the active site of the catalytic moiety to produce the chemically programmed antibody. The invention also encompasses chemically programmed antibodies formed by these methods, methods for their use, and pharmaceutical compositions, as well as proadaptors and conjugates including them. Chemically programmed antibodies are useful for the treatment of cancer, particularly in metastasis.

Targeting Compounds

US Patent:
2013017, Jul 4, 2013
Filed:
Feb 26, 2013
Appl. No.:
13/777680
Inventors:
The Scripps Research Institute - La Jolla CA, US
Christoph Rader - La Jolla CA, US
Subhash C. Sinha - La Jolla CA, US
Richard A. Lerner - La Jolla CA, US
Assignee:
THE SCRIPPS RESEARCH INSTITUTE - La Jolla CA
International Classification:
A61K 49/00
C07K 14/54
C07K 14/71
C12N 15/115
C12N 9/00
C07K 14/47
C07K 14/575
C07K 14/16
C07K 7/06
C07K 5/09
C07D 475/04
US Classification:
424 96, 4241791, 424 852, 4241811, 4351885
Abstract:
The present invention provides antibody targeting compounds in which the specificity of the antibody has been reprogrammed by covalently or noncovalently linking a targeting agent to the combining site of an antibody. By this approach, the covalently modified antibody takes on the binding specificity of the targeting agent. The compound may have biological activity provided by the targeting agent or by a separate biological agent. Various uses of the invention compounds are provided.

Use Of Catalytic Antibodies For Synthesizing Epothilone

US Patent:
6294374, Sep 25, 2001
Filed:
Oct 8, 1999
Appl. No.:
9/415453
Inventors:
Subhash C. Sinha - San Diego CA
Richard A. Lerner - La Jolla CA
Carlos F. Barbas - Del Mar CA
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
C12S 1300
US Classification:
435280
Abstract:
Three monoclonal aldolase antibodies, generated against a. beta. -diketone hapten by reactive immunization, catalyzed rapid and highly enantioselective retro-aldol reactions providing ent-9a-k by kinetic resolution. Compounds 9a, 9g and 9k were resolved in multi-gram quantities using 0. 005-0. 0004 mol % antibody catalyst. Enantiomerically pure starting materials, 9a-k, are useful synthons for the construction of epothilones A-E (2-6) and their analogs including 13-alkyl derivatives. Previously, the use of compound 9a as a synthon was reported in the preparation of epothilones A-D, 2-5. To further expand this synthon-based strategy, syntheses of epothilone E, 6, 13-methyl epothilone C, 7, and their trans-isomers have been achieved starting from enantiomerically pure thiazole aldols 9g and 9a, respectively, prepared by large-scale antibody catalyzed resolutions.

Possible Relatives

Debajyoti Sinha  Deepa C Sinha  Dev J Sinha  Dinesh C Sinha  Dipti Sinha  Divyendu Sinha  Doreen M Sinha  Subhash Sethi  Subhash Arora  Subhash C Chauhan 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.